CG Oncology (CGON) Receivables (2023 - 2026)

CG Oncology (CGON) has 4 years of Receivables data on file, last reported at $1.3 million in Q1 2026.

• Quarterly Receivables rose 269.57% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (up 269.57% YoY) and the FY2025 annual result came in at $688000.0, changed N/A from the prior year.
• Receivables rose to $1.3 million in Q1 2026, from $688000.0 in the prior quarter.
• In the past five years, Receivables ranged from a high of $1.3 million in Q1 2026 to a low of $92000.0 in Q4 2023.
• A 4-year average of $438777.8 and a median of $345000.0 in 2025 frame the typical range for Receivables.
• The widest YoY moves for Receivables: up 275.91% in 2025, down 125.49% in 2025.
• Tracing CGON's Receivables over 4 years: stood at $92000.0 in 2023, then jumped by 48.91% to $137000.0 in 2024, then surged by 402.19% to $688000.0 in 2025, then jumped by 85.32% to $1.3 million in 2026.
• The last three Receivables figures came in at $1.3 million (Q1 2026), $688000.0 (Q4 2025), and $515000.0 (Q3 2025), per Business Quant data.